CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Apr. 30, 2024	Apr. 30, 2023
Cash flows from operating activities:
Net loss	$ (317,816)	$ (226,064)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	40,221	23,163
Non-cash operating lease costs	13,722	12,869
Amortization of deferred commissions	22,764	17,672
Stock-based compensation, net of amounts capitalized	331,936	264,509
Net accretion of discounts on investments	(11,992)	(15,331)
Net realized and unrealized losses on strategic investments in equity securities	20,695	2,414
Deferred income tax	0	(8,868)
Other	669	9,978
Changes in operating assets and liabilities, net of effects of business combinations:
Accounts receivable	579,319	362,893
Deferred commissions	(14,940)	(16,440)
Prepaid expenses and other assets	(1,111)	5,527
Accounts payable	21,244	(3,093)
Accrued expenses and other liabilities	(54,688)	(8,542)
Operating lease liabilities	(13,374)	(10,763)
Deferred revenue	(261,181)	(110,480)
Net cash provided by operating activities	355,468	299,444
Cash flows from investing activities:
Purchases of property and equipment	(16,519)	(6,970)
Capitalized internal-use software development costs	(7,404)	(9,341)
Cash paid for business combinations, net of cash, cash equivalents, and restricted cash acquired	0	(123,112)
Purchases of investments	(1,078,261)	(1,037,286)
Sales of investments	30,360	5,652
Maturities and redemptions of investments	921,395	808,844
Settlement of cash flow hedges	(749)	0
Net cash used in investing activities	(151,178)	(362,213)
Cash flows from financing activities:
Proceeds from exercise of stock options	10,686	15,370
Proceeds from issuance of common stock under employee stock purchase plan	46,735	37,065
Taxes paid related to net share settlement of equity awards	(174,590)	(84,399)
Repurchases of common stock	(516,329)	(191,694)
Net cash used in financing activities	(633,498)	(223,658)
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	(2,633)	535
Net decrease in cash, cash equivalents, and restricted cash	(431,841)	(285,892)
Cash, cash equivalents, and restricted cash—beginning of period	1,780,977	956,731
Cash, cash equivalents, and restricted cash—end of period	1,349,136	670,839
Supplemental disclosures of non-cash investing and financing activities:
Property and equipment included in accounts payable and accrued expenses	16,793	8,071
Stock-based compensation included in capitalized software development costs	9,295	11,719
Unpaid taxes related to net share settlement of equity awards included in accrued expenses and other current liabilities	9,354	4,657
Reconciliation of cash, cash equivalents, and restricted cash:
Cash and cash equivalents	1,330,411	653,014
Restricted cash—included in other assets and prepaid expenses and other current assets	18,725	17,825
Total cash, cash equivalents, and restricted cash	$ 1,349,136	$ 670,839